EA
KPTI icon

Emerald Acquisition’s Karyopharm Therapeutics KPTI Stock Holding History

Emerald Acquisition’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$139K Buy
955
+302
+46% +$36.3K ﹤0.01% 2764
2016
Q2 		$66K Buy
+653
New +$84.8K ﹤0.01% 2889

Other funds holding KPTI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Emerald Acquisition's KPTI Position: Q3 2016 in Review

Emerald Acquisition increased its Karyopharm Therapeutics (KPTI) stake by 46% in Q3 2016, buying an estimated $36.3K and bringing the position to 955 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #2764.

Emerald Acquisition first reported a position in KPTI in Q2 2016 and has held it in 2 quarters since. 79 funds tracked by Wall St. Rank hold KPTI as of Q3 2016.

  • Emerald Acquisition held 955 shares of Karyopharm Therapeutics worth $139K as of Q3 2016.
  • Emerald Acquisition bought 302 Karyopharm Therapeutics shares in Q3 2016, an estimated $36.3K.
  • Karyopharm Therapeutics made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2764 holding.
  • Emerald Acquisition first reported a position in Karyopharm Therapeutics in Q2 2016 and has held it in 2 quarters since.
  • 79 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.